Previous 10 | Next 10 |
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...
2024-04-05 18:30:02 ET Stephens analyst issues BUY recommendation for NTRA on April 5, 2024 05:00PM ET. The previous analyst recommendation was Buy. NTRA was trading at $96.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...
Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $95.17. So far today, approximately 361.85k shares have been exchanged, as compared to an average 30-day volume of 1.38M shares. Natera, Inc., a diagnostics company, develops and commercializ...
2024-04-05 10:00:07 ET Read the full article on Seeking Alpha For further details see: Natera upgraded at Bernstein on gross margin trajectory
Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 ...
2024-04-03 15:44:21 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera GAAP EPS of -$0.65 beats by $0.06, revenue of $311.1M beats by $23.78M Natera Q4 2023 Earn...
News, Short Squeeze, Breakout and More Instantly...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the Internationa...